Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease

Journal of Clinical Pathology

Volumn 50, Issue 2, 1997, Pages 157-160

  Akenami, F O T ^a   Koskiniemi, M ^a   Farkkila M ^b   Vaheri, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Department of Neurology ^*

Author keywords

Cerebrospinal fluid; Neurological disease; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; ENCEPHALITIS; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; VIRUS MENINGITIS;

EID: 0031050864     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.2.157     Document Type: Article

References (33)

1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
2. Loskutoff DJ. Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Semin Thromb Hemost 1988;14:100-9.
3. Kruithof EKO. Plasminogen activator inhibitors - a review. Enzyme 1988;40:113-21.
4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen K, Nielsen L, Skriver L. Plasminogen activators, tissue degradation and cancer. Acta Cancer Res 1985;44:139-266.
5. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
6. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990;88:1-19.
7. Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977;74:3903-7.
8. Simpson AJ, Booth NA, Moor NR, Benneth B. Distribution of plasminogen activator inhibitor (PAI-1) in tissue. J Clin Pathol 1991;44:139-43.
9. Caccamo DV, Keohane ME, McKeever PE. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. Mod Pathol 1994;7:99-104.
10. Kono S, Rao JS, Bruner JM, Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumours. J Neuropathol Exp Neurol 1994;53: 256-62.
11. Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, et al. Expression and localization of urokinasetype plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54:3656-61.
12. Sawey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-β, lipopolysaccharide, in tumour necrosis factor-α. J Biol Chem 1989;264:10396-401.
13. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-β induction of type 1 plasminogen activator inhibitor. J Biol Chem 1987;262:17467-74.
14. De Boer JP, Abbink JJ, Brouwer MC, Meijer C, Roem D, Voorn GP, et al. PAI-1 synthesis in the human hepatoma cell line Hep-G is increased by cytokines - evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991;65:181-5.
15. Morganti-Korsmann MC, Kossman T, Wahl SM. Cytokines and neuropathology. Trends Pharmacol 1992;13:286-91.
16. Wiman B, Chmielweska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984;259: 3644-7.
17. Kruithof EKO. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984;64: 907-13.
18. Wiman B. The role of the fibrinolytic systems. J Lab Clin Med 1985;105:265-70.
19. Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
20. Isacsson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. Acta Chir Scand 1972;138:313-9.
21. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985;75:818-24.
22. Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator during pregnancy. Thromb Haemost 1984;52:124-6.
23. Sutton R, Keohane ME, Van der Berg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994;5:167-71.
24. Sawaya R, Rayford A, Kono S, Ang KK, Feng Y, Stephens CL, et al. Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo. J Neurosurg 1994;81:381-7.
25. Gijtenbeek JM, Emeis JJ, Van-der-Sande JJ, Lulf RE. Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema? Clin Neurol Neurosurg 1994;96:305-9.
26. De Vries TJ, Mooy CM, Van Balken MR, Luyten GP, Quax PH, Verspaget HW, et al. Components of the plasminogen activation system in uveal melanoma - a clinicopathological study. J Pathol 1995;175:59-67.
27. Akenami FOT, Sirén V, Koskiniemi M, Siimes MA, Teräväinen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996;49:577-80.
28. Rånby M, Sundell JB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989;62: 917-22.
29. Kruithof KO, Nicolosa G, Bachmann K Plasminogen activator inhibitor 1: development of radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987;70:1645-53.
30. Koskiniemi M, Vaheri A, Taskinen E. Cerebrospinal fluid alterations in herpes simplex virus encephalitis. Rev Infect Dis 1984;6:608-17.
31. Rao JS, Chen M, Festoff BW. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in the normal human cerebrospinal fluid. J Neurosci Res 1993;34:340-5.
32. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986;163: 1260-6.
33. Wada H, Kumeda Y, Ogasawara Z, Ohiwa M, Kaneko T, Tamaki S, et al. Plasminogen activators and their inhibitors in leukaemic cell homogenates. Am J Hematol 1993;42: 166-70.